Vaccine with beta-glucan for high-risk neuroblastoma
Part of Cancer clinical trials.
This trial tests a vaccine combined with beta-glucan, a natural immune booster, to help keep high-risk neuroblastoma from coming back. It is for patients who have finished standard treatment and achieved complete remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk neuroblastoma that is currently in complete remission after treatment
- If this is your first remission, it must have lasted at least 6 months after finishing immunotherapy (like anti-GD2 antibody)
- You may be in your second or later remission after a relapse
- It has been at least 3 weeks but less than 6 months since your last systemic treatment
- You have recovered from severe side effects of prior therapy, with adequate blood counts
- You are not allergic to the vaccine ingredients (KLH, QS-21, OPT-821, or beta-glucan)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a vaccine to a substance called beta-glucan (which may help the immune system) and a growth factor drug called GM-CSF can help prevent high-risk neuroblastoma from coming back. You would receive these as an injection or IV. The study is for people whose cancer is in remission or has responded well to prior treatment.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This trial tests a new combination of medicines for children with high-risk neuroblastoma that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a new drug combination (dinutuximab-beta plus chemotherapy) for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if adding this targeted therapy to standard chemo improves outcomes.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.